VANCOUVER, BC--(Marketwired - May 24, 2016) - Breathtec BioMedical,
Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the "Company" or "Breathtec"),
a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class
breath analysis devices for the early detection of life threatening diseases is pleased to announce that further to its press
release of April 13, 2016, it has now issued 1,000,000 common shares of the Company ("Shares") to Technion
Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion -- Israel
Institute of Technology ("Technion"), pursuant to a license agreement dated as of March 16, 2016 between the
Company and Technion with respect to a non-exclusive license to the NA-Nose technology patents and know-how to enable commercial
advancements in the field of infections detection.
In addition, further to the Company's press release of April 19, 2016 with respect to the engagement of Professor Hossam Haick
of Technion pursuant to a 12 month consulting services agreement, subject to regulatory approval, the Company will issue 60,000
Shares (subject to adjustment in certain circumstances) on or before April 31, 2017 as partial consideration for his
services.
Shares issued to Technion are subject to a 4 month hold period pursuant to applicable securities laws which expires on
September 5, 2016. Shares issued to Professor Hossam Haick will be subject to a 4 month hold period from the date of issuance
pursuant to applicable securities laws.
Professor Haick is best known for developing the NA-NOSE technology that can be
used to detect disease by mechanically "smelling" elements in the breath of potential sufferers. Certain diseases produce
chemicals called volatile organic compounds (VOCs), which easily evaporate into the air and produce a discernible scent profile.
Haick's Na-NOSE chip detects the unique "signature" of VOCs in exhaled breath.
In related news, Professor Dr. Haick has recently been acclaimed as one of the world's most "Good" people, as noted by GOOD Magazine, an international publication that recognizes researchers for the
benefits of their work for humanity. According to the magazine publishers, Haick is one of the 100 most influential people in the
world who are changing the world in a positive manner. The GOOD 100 are "spearheading change" in the areas of science, education,
and business, said the magazine, and Haick, among them, "refuses to accept the existing reality as the end of the story. Not one
of the 100 people we have chosen operates out of a desire for fame -- which is precisely why it is important to recognize their
activity."
Besides the GOOD recognition, Dr. Haick was also recently presented with the Humboldt Research Award, which recognizes top research done
throughout the world in cooperation with research institutes in Germany. Awarded by the Alexander von Humboldt Foundation, the
prize is given to prominent researchers who have significantly influenced their fields of study in cooperation with research
institutes in Germany. It is granted in recognition of a researcher's achievements as a whole -- discoveries, theories, and
insights.
Mr. Kal Malhi, President of Breathtec Biomedical notes, "We are truly excited by the prospects ahead. This agreement
represents a major leap forward in our quest to commercialize the best breath analysis technologies for the detection of disease.
Our technical partners are world-class, and with the expert direction of Prof. Haick we are extremely well served. With the close
of this agreement we are rapidly moving ahead and arrangements to ship the prototype technology to our research and development
team are already underway."
For more information, please visit: www.breathtecbiomedical.com.
ON BEHALF OF THE BOARD
"Kal Malhi"
President & Director
CAUTIONARY DISCLAIMER STATEMENT: The applicable securities exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of the content of this news release.
This news release contains forward-looking statements relating to product development, licensing, commercialization and
regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified
by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements
of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and actual results and future events could differ materially from those
anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's
expectations include the failure to satisfy the conditions of the applicable securities exchange and other risks detailed
from time to time in the filings made by the Company with securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made as of the date of this news release and the Company will
update or revise publicly any of the included forward-looking statements as expressly required by applicable law.